MedTrace Logo

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

NCT06679413 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-03-30

No results posted yet for this study

Summary

The purpose of the study is to assess the single-dose pharmacokinetics (PK) of 3 probe drugs (midazolam, bupropion, and metformin) before and after repeat doses of ZX008

Conditions

  • Healthy Study Participants

Interventions

DRUG

midazolam

Study participants will receive a pre specified single oral dose of probe drug midazolam on Day 1 and Day 22 of the study

DRUG

metformin

Study participants will receive a pre-specified single oral dose of probe drug metformin on Day 1 and Day 22 of the study

DRUG

bupropion

Study participants will receive a pre-specified single oral dose of probe drug bupropion on Day 1 and Day 22 of the study

DRUG

fenfluramine HCl

Study participants will receive pre-specified repeated oral doses of fenfluramine HCl (ZX008) from Day 6 to 26 during the study

Sponsors & Collaborators

  • UCB BIOSCIENCES, Inc.

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273 (UCB)

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-04
Primary Completion
2025-06-12
Completion
2025-06-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06679413 on ClinicalTrials.gov